Sesamin inhibits lipopolysaccharide-induced proliferation and
invasion through the p38-MAPK and NF-κB signaling
pathways in prostate cancer cells

Xu,Peiyuan; Cai,Fei; Liu,Xiaofei; Guo,Lele

doi:10.3892/or.2015.3888

Sesamin inhibits lipopolysaccharide-induced proliferation and invasion through the p38-MAPK and NF-κB signaling pathways in prostate cancer cells

Authors:
- Peiyuan Xu
- Fei Cai
- Xiaofei Liu
- Lele Guo
View Affiliations

Affiliations: Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
Published online on: March 31, 2015 https://doi.org/10.3892/or.2015.3888
Pages: 3117-3123

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sesamin, a lipid-soluble lignan, is one of the major constituents of sesame. Previous studies have reported that sesamin induces growth inhibition in human cancer cells, particularly prostate cancer cells. In the present study, we mainly explored the mechanism underlying the protective effect of sesamin on prostate cancer cell proliferation and invasion induced by lipopolysaccharide (LPS). We found that the proliferation of PC3 cells, as determined using the MTT assay, and the expression of cyclin D1, COX-2, Bcl-2 and survivin proteins elevated by LPS were distinctly inhibited by sesamin in a dose-dependent manner. Meanwhile, the ability of PC3 cell invasion, as determined using the Transwell assay and the expression of matrix metalloproteinase 9 (MMP-9), intercellular adhesion molecule-1 (ICAM-1) and vascular endothelial growth factor (VEGF) proteins increased by LPS were obviously reduced by sesamin in a dose-dependent manner. In addition, the accumulation of TGF-α and interleukin-6 (IL-6) production induced by LPS in the culture supernatant was found to be decreased dose-dependently with sesamin pretreatment in PC3 cells using the enzyme-linked immunosorbent assay (ELISA) kit. Furthermore, phosphorylation of the p38 protein and nuclear factor (NF)-κB activity in the PC3 cells were enhanced by LPS and further inhibited with sesamin, SB203580 pretreatment or p38-siRNA transfection, respectively. Sesamin or SB203580 pretreatment obviously inhibited PC3 cells-derived tumor growth induced by LPS in vivo. Taken together, these results suggest that the potential ability of sesamin to downregulate the secretion of cytokines and the expression of cell proliferative- and invasive-related gene products induced by LPS was shown to be via the p38 mitogen-activated protein kinase (p38-MAPK) and NF-κB signaling pathways, which may be one of the mechanisms of the anticancer activity of this sesamin agent in prostate cancer cells.

View Figures

View References

1	Lin SS, Clarke CA, Prehn AW, Glaser SL, West DW and O’Malley CD: Survival differences among Asian subpopulations in the United States after prostate, colorectal, breast, and cervical carcinomas. Cancer. 94:1175–1182. 2002. View Article : Google Scholar : PubMed/NCBI
2	Hsing AW, Tsao L and Devesa SS: International trends and patterns of prostate cancer incidence and mortality. Int J Cancer. 85:60–67. 2000. View Article : Google Scholar
3	Hsing AW and Devesa SS: Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev. 23:3–13. 2001. View Article : Google Scholar : PubMed/NCBI
4	Sonn GA, Aronson W and Litwin MS: Impact of diet on prostate cancer: a review. Prostate Cancer Prostatic Dis. 8:304–310. 2005. View Article : Google Scholar : PubMed/NCBI
5	Schetter AJ, Heegaard NH and Harris CC: Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis. 31:37–49. 2010. View Article : Google Scholar :
6	Coussens LM and Werb Z: Inflammation and cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
7	Mantovani A: Cancer: inflammation by remote control. Nature. 435:752–753. 2005. View Article : Google Scholar : PubMed/NCBI
8	Hsu RY, Chan CH, Spicer JD, Rousseau MC, Giannias B, Rousseau S and Ferri LE: LPS-induced TLR4 signaling in human colorectal cancer cells increases beta1 integrin-mediated cell adhesion and liver metastasis. Cancer Res. 71:1989–1998. 2011. View Article : Google Scholar : PubMed/NCBI
9	Li J, Chong T, Wang Z, Chen H and Li H, Cao J, Zhang P and Li H: A novel anti-cancer effect of resveratrol: reversal of epithelial mesenchymal transition in prostate cancer cells. Mol Med Rep. 10:1717–1724. 2014.PubMed/NCBI
10	Im HJ, Park NH, Kwon YJ, Shin S, Kim D and Chun YJ: Bacterial lipopolysaccharides induce steroid sulfatase expression and cell migration through IL-6 pathway in human prostate cancer cells. Biomol Ther (Seoul). 20:556–561. 2012. View Article : Google Scholar
11	Michalaki V, Syrigos K, Charles P and Waxman J: Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer. 90:2312–2316. 2004.PubMed/NCBI
12	Balkwill F: Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev. 13:135–141. 2002. View Article : Google Scholar : PubMed/NCBI
13	Szlosarek PW and Balkwill FR: Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol. 4:565–573. 2003. View Article : Google Scholar : PubMed/NCBI
14	Ayre JE: Cervical cancer: chronic inflammation, stress and adaptation factors. Acta Unio Int Contra Cancrum. 12:20–27. 1956.PubMed/NCBI
15	Dalgleish AG and O’Byrne KJ: Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer. Adv Cancer Res. 84:231–276. 2002. View Article : Google Scholar : PubMed/NCBI
16	Farrow B and Evers BM: Inflammation and the development of pancreatic cancer. Surg Oncol. 10:153–169. 2002. View Article : Google Scholar : PubMed/NCBI
17	Nelson WG, De Marzo AM, DeWeese TL and Isaacs WB: The role of inflammation in the pathogenesis of prostate cancer. J Urol. 172:S6–S12. 2004. View Article : Google Scholar : PubMed/NCBI
18	Schwartsburd PM: Chronic inflammation as inductor of pro-cancer microenvironment: pathogenesis of dysregulated feedback control. Cancer Metastasis Rev. 22:95–102. 2003. View Article : Google Scholar : PubMed/NCBI
19	Tiwari N, Gheldof A, Tatari M and Christofori G: EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol. 22:194–207. 2012. View Article : Google Scholar : PubMed/NCBI
20	Chen MC, Chang WW, Kuan YD, Lin ST, Hsu HC and Lee CH: Resveratrol inhibits LPS-induced epithelial-mesenchymal transition in mouse melanoma model. Innate Immun. 18:685–693. 2012. View Article : Google Scholar : PubMed/NCBI
21	Lu JN, Lee WS, Kim MJ, Yun JW, Jung JH, Yi SM, Jeong JH, Kim HJ, Choi YH, Kim GS, et al: The inhibitory effect of anthocyanins on Akt on invasion and epithelial-mesenchymal transition is not associated with the anti-EGFR effect of the anthocyanins. Int J Oncol. 44:1756–1766. 2014.PubMed/NCBI
22	Yang CS and Wang X: Green tea and cancer prevention. Nutr Cancer. 62:931–937. 2010. View Article : Google Scholar : PubMed/NCBI
23	Gloria NF, Soares N, Brand C, Oliveira FL, Borojevic R and Teodoro AJ: Lycopene and beta-carotene induce cell-cycle arrest and apoptosis in human breast cancer cell lines. Anticancer Res. 34:1377–1386. 2014.PubMed/NCBI
24	Akl MR, Ayoub NM, Abuasal BS, Kaddoumi A and Sylvester PW: Sesamin synergistically potentiates the anticancer effects of γ-tocotrienol in mammary cancer cell lines. Fitoterapia. 84:347–359. 2013. View Article : Google Scholar
25	Tanabe H, Kuribayashi K, Tsuji N, Tanaka M, Kobayashi D and Watanabe N: Sesamin induces autophagy in colon cancer cells by reducing tyrosine phosphorylation of EphA1 and EphB2. Int J Oncol. 39:33–40. 2011.PubMed/NCBI
26	Yokota T, Matsuzaki Y, Koyama M, Hitomi T, Kawanaka M, Enoki-Konishi M, Okuyama Y, Takayasu J, Nishino H, Nishikawa A, et al: Sesamin, a lignan of sesame, down-regulates cyclin D1 protein expression in human tumor cells. Cancer Sci. 98:1447–1453. 2007. View Article : Google Scholar : PubMed/NCBI
27	Deng P, Wang C, Chen L, Wang C, Du Y, Yan X, Chen M, Yang G and He G: Sesamin induces cell cycle arrest and apoptosis through the inhibition of signal transducer and activator of transcription 3 signalling in human hepatocellular carcinoma cell line HepG2. Biol Pharm Bull. 36:1540–1548. 2013. View Article : Google Scholar : PubMed/NCBI
28	Wang HM, Cheng KC, Lin CJ, Hsu SW, Fang WC, Hsu TF, Chiu CC, Chang HW, Hsu CH and Lee AY: Obtusilactone A and (−)-sesamin induce apoptosis in human lung cancer cells by inhibiting mitochondrial Lon protease and activating DNA damage checkpoints. Cancer Sci. 101:2612–2620. 2010. View Article : Google Scholar : PubMed/NCBI
29	Harikumar KB, Sung B, Tharakan ST, Pandey MK, Joy B, Guha S, Krishnan S and Aggarwal BB: Sesamin manifests chemopreventive effects through the suppression of NF-kappa B-regulated cell survival, proliferation, invasion, and angiogenic gene products. Mol Cancer Res. 8:751–761. 2010. View Article : Google Scholar : PubMed/NCBI
30	Liu L, Ge D, Ma L, Mei J, Liu S, Zhang Q, Ren F, Liao H, Pu Q, Wang T, et al: Interleukin-17 and prostaglandin E2 are involved in formation of an M2 macrophage-dominant microenvironment in lung cancer. J Thorac Oncol. 7:1091–1100. 2012. View Article : Google Scholar : PubMed/NCBI
31	Bieniek J, Childress C, Swatski MD and Yang W: COX-2 inhibitors arrest prostate cancer cell cycle progression by down-regulation of kinetochore/centromere proteins. Prostate. 74:999–1011. 2014. View Article : Google Scholar : PubMed/NCBI
32	Wang L, Zhu R, Huang Z, Li H and Zhu H: Lipopoly-saccharide-induced toll-like receptor 4 signaling in cancer cells promotes cell survival and proliferation in hepatocellular carcinoma. Dig Dis Sci. 58:2223–2236. 2013. View Article : Google Scholar : PubMed/NCBI
33	Li Y, Fan L, Sun Y, Zhang D, Yue Z, Niu Y, Meng J, Yang T, Liu W and Mei Q: An apple oligogalactan suppresses endotoxin-induced cyclooxygenase-2 expression by inhibition of LPS pathways. Int J Biol Macromol. 61:75–81. 2013. View Article : Google Scholar : PubMed/NCBI
34	Lee CC, Liu KJ, Wu YC, Lin SJ, Chang CC and Huang TS: Sesamin inhibits macrophage-induced vascular endothelial growth factor and matrix metalloproteinase-9 expression and proangiogenic activity in breast cancer cells. Inflammation. 34:209–221. 2011. View Article : Google Scholar
35	Lu T and Stark GR: Cytokine overexpression and constitutive NFkappaB in cancer. Cell Cycle. 3:1114–1117. 2004. View Article : Google Scholar : PubMed/NCBI
36	Rousseau MC, Hsu RY, Spicer JD, McDonald B, Chan CH, Perera RM, Giannias B, Chow SC, Rousseau S, Law S, et al: Lipopolysaccharide-induced toll-like receptor 4 signaling enhances the migratory ability of human esophageal cancer cells in a selectin-dependent manner. Surgery. 154:69–77. 2013. View Article : Google Scholar : PubMed/NCBI
37	Zhang Y, Guo Z, Du T, Chen J, Wang W, Xu K, Lin T and Huang H: Prostate specific membrane antigen (PSMA): a novel modulator of p38 for proliferation, migration, and survival in prostate cancer cells. Prostate. 73:835–841. 2013. View Article : Google Scholar
38	Leelahavanichkul K, Amornphimoltham P, Molinolo AA, Basile JR, Koontongkaew S and Gutkind JS: A role for p38 MAPK in head and neck cancer cell growth and tumor-induced angiogenesis and lymphangiogenesis. Mol Oncol. 8:105–118. 2014. View Article : Google Scholar :
39	Sukhtankar D, Okun A, Chandramouli A, Nelson MA, Vanderah TW, Cress AE, Porreca F and King T: Inhibition of p38-MAPK signaling pathway attenuates breast cancer induced bone pain and disease progression in a murine model of cancer-induced bone pain. Mol Pain. 7:812011. View Article : Google Scholar : PubMed/NCBI